UV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid
Transformative Medical Materials · 2026-09 · 1 (2) · 100005
DOI: 10.1016/j.trmm.2026.100005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transformative Medical Materials, 2026-09. Verfasst von Aditi Sonone und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Dasatinib (DTB) is an effective tyrosine kinase inhibitor with promising therapeutic potential in the treatment of Glioblastoma (GBM); however, the use of this drug is restricted by the low ability of the drug to penetrate the brain and the side effects of the drug in the body. Nanoparticle-based intranasal drug delivery systems have been recognized as an effective way to improve the direct nose-to-brain delivery of drugs. In the current study, a simple, rapid, and cost-effective UV-Visible spectrophotometric method was developed and validated for the quantitative estimation of the drug DTB in methanol, Milli-Q water, simulated nasal fluid (SNF), and DTB-loaded chitosan nanoparticles. The λmax of the drug was observed at 322 nm, and the proposed method was found to be linear in the range of 2-10 μg/mL with correlation coefficient (r² > 0.99) and the regression equation y = 0.0172x - 0.03762. The proposed method was validated according to the ICH guidelines and was found to be precise (%RSD < 2%), accurate (98-101% recovery), and sensitive with LOD values of 0.35-0.37 μg/mL and LOQ values of 0.84-0.86 μg/mL. The validated method was successfully employed for the characterization of DTB-loaded chitosan nanoparticles intended for intranasal administration. The nanoparticles had a particle size ranging from 146 ± 1.24 to 150 ± 2.11 nm, zeta potential of +24.67 ± 1.03 mV, and an entrapment efficiency of 63.48 ± 1.17%. Moreover, the formulation had a sustained drug release profile with 94.83 ± 1.34% drug release over 24 hours. Notably, the formulation had enhanced cellular uptake in glioma cells, 41.36 ± 0.28 μg/10⁵ cells, as opposed to the plain drug, 30.74 ± 0.57 μg/10⁵ cells. Stability studies indicated that the formulation remained stable for 90 days at 25°C/60% RH. Therefore, the developed UV method is appropriate for the analysis of DTB in its nanoparticle formulations, which is useful for the development of an intranasal nanoparticulate system for the brain targeting of GBM therapy.
Zitieren
APA
Sonone, A., Thakur, M., Agade, R., Wadher, K., & Trivedi, S. S. (2026). UV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid. Transformative Medical Materials, 1(2), 100005. https://doi.org/10.1016/j.trmm.2026.100005
Vancouver
Sonone A, Thakur M, Agade R, Wadher K, Trivedi SS. UV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid. Transformative Medical Materials. 2026;1(2):100005. doi:10.1016/j.trmm.2026.100005
BibTeX
@article{Sonone2026,
author = {Sonone, Aditi and Thakur, Mansi and Agade, Rishabh and Wadher, Kamlesh and Trivedi, Sagar S.},
title = {UV-visible spectroscopic based quantitative estimation of intranasal dasatinib-encapsulated polymeric nanoparticles in simulated nasal fluid},
journal = {Transformative Medical Materials},
year = {2026},
volume = {1},
number = {2},
pages = {100005},
doi = {10.1016/j.trmm.2026.100005}
}
EUVIMED